Recipients Awarded in 2016
Savita G. Bhakta, MD
Department of Psychiatry, UC San Diego
Mentor: Neal Swerdlow, MD, PhD
Project Title: Tolcapone Effects on Cognitive Control in Psychosis: Neural Basis and Biomarker Predictors
Abstract: Functional impairment in chronic psychotic disorders such as schizophrenia is linked to disturbances in cognitive processes, including those that guide the ability to inhibit inaccurate responses, termed “cognitive control.” Furthermore, these disturbances in cognitive control processes have a devastating impact on patients, families and our society, and are not effectively treated by currently available medications. Tolcapone, a medication used in the treatment of Parkinson’s disease, has been found to improve performance on certain cognitive tasks in healthy subjects and is therefore being considered as a potential cognitive enhancing medication for patients with schizophrenia. This application is the first to investigate the cognitive enhancing effects of tolcapone on cognitive control task performance in patients with chronic psychotic disorder. In addition, tolcapone’s effect on cognitive control performance will be corroborated with changes in the distribution of electrical activity measured across the surface of the brain. The latter will be measured using plastic electrodes placed on the scalp and over muscles surrounding the eye. The findings will inform us about the way brain activity controls our ability to inhibit unwanted behavioral responses, and how to strengthen that ability in patients using tolcapone. Importantly, these findings will provide a strong basis for developing future cognitive enhancing therapeutics in patients with chronic psychotic disorders that will ultimately aid in improving their socio-occupational functioning.
Jill Blumenthal, MD
Department of Medicine, UC San Diego
Mentor: Steffanie Strathdee, PhD
Project Title: Barriers and Facilitators to PrEP Adherence in High-Risk HIV-uninfected Women in Southern California
Abstract: Antiretroviral-based HIV prevention strategies, including pre-exposure prophylaxis (PrEP) for HIV-uninfected individuals, are promising interventions for reducing the spread of HIV. In the United States, the HIV epidemic has largely impacted men; however, women are increasingly affected. Clinical trials using oral PrEP in women have had mixed results with some showing efficacy and others finding none due to lack of adherence, leading to confusion around whether daily oral PrEP is a viable HIV prevention tool for women. Moreover, studies suggest that women may require nearly perfect adherence to oral PrEP to be protective against HIV acquisition. In the US, there has been limited attention directed towards understanding predictors of PrEP adherence in high-risk women. Through the parent AEGIS PrEP Demonstration Project in women, we will recruit high-risk HIV-uninfected women for questionnaires and in-depth interviews to improve our understanding of barriers and facilitators to PrEP, with attention to women in serodiscordant partnerships. These findings could have implications for using PrEP in controlling the HIV epidemic in other parts of Southern California and may ultimately be applicable to other parts of the US.
Brigid Boland, MD
Department of Medicine, UC San Diego
Mentor: John Chang, MD
Project Title: Identifying Biomarkers Predictive of Clinical and Endoscopic Response to Vedolizumab in Inflammatory Bowel Disease
Abstract: A significant proportion of individuals with inflammatory bowel disease (IBD) do not have a sustained response to the standard therapies used to treat it. Vedolizumab, a novel medication that prevents inflammatory cells from entering the gastrointestinal tract where they cause inflammation, was recently approved and expanded the available treatment options. As compared to other therapies, vedolizumab takes longer to have a clinical effect, and typical markers of inflammation are not affected by vedolizumab. As a consequence, there is a significant need to discover early and convenient markers to predict whether an individual will respond to vedolizumab before a patient feels better. Such a predictor would help determine whether or not to continue an expensive medication with potential for side effects. This proposal aims to identify early markers of response to vedolizumab and determine which ones will predict symptom improvement and healing of gastrointestinal inflammation. Blood samples and symptom scores will be obtained over time from patients with IBD being treated with vedolizumab as part of routine care to measure markers of response to therapy. Endoscopies will be performed to evaluate response to vedolizumab at which time intestinal biopsies will be obtained. Reproducible symptom and endoscopic scores will be used to assess which markers are the most useful in predicting response to therapy. In summary, this project will identify predictors of which patients will respond to vedolizumab, providing critical information to both patients and providers to enhance the management of IBD and improve our scientific understanding of how the novel medication vedolizumab works.
Anjan Debnath, PhD
Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
Mentor: James McKerrow, MD, PhD
Project Title: Targeting Cysteine Protease in Primary Amebic Meningoencephalitis
Abstract: Primary amebic meningoencephalitis (PAM) is a rapidly fatal infection caused by the free-living ameba Naegleria fowleri, popularly known as “brain-eating ameba.” PAM occurs principally in healthy children with a history of recent exposure to warm fresh water. While as yet not a reportable disease, a total of 132 cases have been documented in the U.S. and only three people survived. The drug of choice in treating PAM is amphotericin B, but its use is associated with severe adverse effects. Moreover, very few patients treated with amphotericin B have survived PAM. Therefore, development of fast-acting, efficient drugs is a critical unmet need to avert future deaths of children. Cysteine protease is a critical enzyme of N. fowleri that plays a role in the progression of PAM causing extensive inflammation in the brain. In this research, we will test the hypothesis that blockade of cysteine protease activity of N. fowleri by small molecule inhibitors will be detrimental to N. fowleri survival. Our preliminary studies identified few cysteine protease inhibitors that are effective to inhibit the enzyme activity of N. fowleri and provide the first evidence of the efficacy of these inhibitors against N. fowleri. In a unique approach of targeting pathogen enzyme and using an automated technology, brain-active compounds will be identified that will not only effectively kill ameba but will decrease the risk of treatment failure. These inhibitors will be used as a basis to develop drugs to treat Naegleria infection, thereby saving children’s lives from this severe and tragic disease.
Farhad Imam, MD, PhD
Department of Pediatrics, UC San Diego
Mentor: Gabriel Haddad, MD
Project Title: Genetic and Molecular Characterization of Hypoxia Resistance via Preconditioning for Prevention of Brain Injury in Term and Preterm Newborn Infants
Abstract: Hypoxia is a major cause of tissue and organ injury and can cause debilitating disease for infants via birth asphyxia and cerebral palsy, or in adults via heart attack and stroke. A widespread, natural protective phenomenon termed “hypoxic preconditioning” occurs when prior hypoxia exposure results in robust hypoxia resistance, but it is poorly understood. We have developed a novel animal model of hypoxic preconditioning and propose genetic and genomic investigations in order to better define its protective mechanisms and thereby contribute to novel therapeutic strategies for hypoxia-induced disease in humans.
Successful identification of a neuroprotective drug target that could activate the preconditioned state and protect against hypoxic injury would make a tremendous impact for infants with neonatal encephalopathy. Improvement upon the current strategy of supportive management to a preventive therapy is therefore of central importance for this devastating and common disease. Moreover, our proposed metabolic studies of the preconditioned state could identify biomarkers of predictive value for risk stratification of patients prior to initiation of therapy, assessment of response to therapy, and/or companion diagnostics.
Joanna Jacobus, PhD
Department of Psychiatry, UC San Diego
Mentor: Susan Tapert, PhD
Project Title: Cognitive Bias Modification Training to Reduce Marijuana Use in Adolescents
Abstract: Marijuana is the most commonly used illicit drug in the United States, and recent years have shown declines in young people’s views that taking this drug is risky. This project will be a first step in development of a novel computerized intervention for marijuana misuse that targets implicit cognitive processing of drug stimuli and neural vulnerabilities that maintain addiction. If an approach-bias to marijuana cues can be modified and proven useful in reducing problematic marijuana use, computerized cognitive bias modification paradigms may be added to existing behavioral treatment modalities to improve treatment outcomes, thereby reducing costs to patients, healthcare, and society.
Eric Roeland, MD
Department of Medicine, UC San Diego
Mentor: Ezra Cohen, MD
Project Title: FIT: Functional and Imaging Testing to Evaluate
Body Composition and Functional Activity in Metastatic Cancer Patients
Abstract: Cancer cachexia is a multifactorial hypermetabolic syndrome characterized by involuntary, ongoing skeletal muscle loss leading to progressive functional impairment. While cancer cachexia has traditionally been defined by a specified percent weight loss over time, weight loss is a late event that does not reflect the underlying pathophysiology or the breadth of its clinical impact. Despite the potential of novel treatment options for cancer cachexia, the current methodological approach to determining patient enrollment and/or demonstrating changes in lean body mass is problematic. Eligibility criteria target late stages of cachexia where treatment is ineffective and there exists no clear guidance on how to demonstrate quantifiable change in lean body mass assessments and physical activity as required for FDA approval. Capturing body composition on computed tomography (CT) scans is promising as these images are already standard part of cancer care and can be utilized and interpreted to allow screening and early identification when interventions have the largest impact. Correlation of CT body composition analysis with physical activity has the potential to revolutionize the prospective study of cancer cachexia by establishing a standard, validated methodological approach that fulfills FDA requirements, decreases patient burden, and minimizes cost. The proposed project is a key initial step. To date, there has been no prospective validation of correlating changes in cross-sectional CT scan skeletal muscle mass with changes in physical activity.
Caroline A. Thompson, PhD, MPH
Division of Epidemiology and Biostatistics, San Diego State University
Mentor: Andrea LaCroix, PhD
Project Title: Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Abstract: Breast cancer is the most commonly diagnosed malignancy among women and one of the most treatable. Early detection through routine mammography screening is recommended, but the starting age and frequency of such screenings is debated. False positive result rates are high, have psychological harms, and, if repeatedly experienced, may reduce return to annual screenings, or impact treatment choices in women subsequently diagnosed with breast cancer. Patient-level factors that may contribute to variation in screening and breast cancer-related clinical pathways are not well understood. Electronic health records (EHR) contain vast amounts of detail reflecting routine clinical care with the potential to expand our understanding of patient choices in breast screening and care, and improve personalized care. EHR research is limited, however, by the structure and complexity of the data, and by the investigator’s often limited knowledge of how the data are generated in the healthcare delivery system. This project is designed to examine how appropriate use of informatics methods and in-depth knowledge of healthcare delivery can allow EHR data to expand our understanding of the pathway from screening to cancer diagnosis, and why patients choose certain treatments.
Recipients Awarded in 2014
Jona Hattangadi-Gluth, MD
Department of Radiation Medicine and Applied Sciences
Mentor: Anders Dale, PhD
Project Title: Quantitative Neuroimaging and Neurocognitive Assessment to Measure Radiation-induced Brain Injury in Non-Targeted Tissue: Implications for Cognitive Preservation
Abstract: Radiation to the brain results in an inevitable decline in neurocognitive function, mediated by tissue injury to white matter and neuronal injury to the hippocampus. With quantitative magnetic resonance imaging (MRI) techniques, we can directly and non-invasively measure such changes. The purpose of this study is to examine radiation-induced imaging changes in normal brain tissue and correlate with neurocognitive outcome. The overarching goal is to better understand these "bystander effects," identifying particularly sensitive brain regions so that future radiation technique scan be optimally designed to mitigate collateral damage.
Frederick Park, MD, PhD
Department of Medicine
Mentor: Tannishtha Reya, PhD
Project Title: Control of Colon Cancer Stem-like Cell Identity by Musashi1
Abstract: The overall objective of this project is to identify signaling factors that confer a stem-like state upon colon cancer cells. This state of gene expression is of direct clinical interest because it has been closely linked to poor clinical outcomes in colon cancer patients. Members of the Reya lab previously showed that an RNA-binding protein called Musashi2 participates in such a pathway during the progression of chronic myelogenous leukemia to blast crisis. The goal of this research is to determine whether Musashi1 acts similarly as a key regulator of the colon cancer stem cell state.
Michael Preziosi, MD
Department of Medicine
Mentor: Donald Guiney, MD
Project Title: Characteristics of Non-Typhoidal Salmonella in Maputo, Mozambique
Abstract: Non-Typhoidal Salmonella (NTS) is the most common foodborne pathogen to cause hospitalization and death in the United States and has recently has emerged as an epidemic in sub-Saharan Africa, where it is a leading cause of invasive disease in young children and patients with AIDS, carrying a mortality rate of 20-25 percent. What is not known is why invasive NTS disease is a major problem in Africa and not the rest of the world. Though there are thousands of serotypes of NTS, a distinct lineage of S. typhimurium, ST313, has spread across sub-Saharan Africa in association with HIV and is largely responsible for this epidemic. Outside of Africa most NTS have animal reservoirs, but there is evidence to suggest that these lineages may be evolving to become adapted to humans in this part of the world. However, all analysis has focused on strains that cause invasive disease in Africa, and little is known about environmental strains or those that cause gastroenteritis or asymptomatic carriage. Furthermore, although a great deal is known about their genetics, little is known about the functional biology of these strains. The objective of this application is to determine to what extent known invasive strains of NTS also cause asymptomatic carriage in humans, and to characterize virulence differences between strains isolated from humans versus environmental sources. Dr. Preziosi's central hypothesis is that epidemic strains of NTS causing invasive disease in children and immunocompromised adults are intestinally carried by human hosts. His long-term goal in achieving these aims is to help discover the source of epidemic NTS in Mozambique and the modes by which it is transmitted so that it may be prevented.
Gabriel Wagner, MD
Department of Medicine, Division of Infectious Diseases
Mentor: Davey Smith, MD
Project Title: HIV-1 Dual Infection and Neurocognitive Impairment
Abstract: An increasingly reported phenomenon, HIV dual infection (DI) is characterized by molecular evidence of two (or more) distinct viral subpopulations within the same host. DI has been associated with increased viral load, accelerated disease progression, faster decline in CD4+ Tcells, and shorter time to AIDS diagnosis1. Given that HIV DI is associated with these markers of disease progression and immunosuppression it is also likely that HIV DI enhances end organ damage often seen during HIV infection. An important organ system that is commonly damaged during HIV infection is the central nervous system (CNS), which leads to a range of neurologic disease manifestations. In fact, HIV-associated neurocognitive disorder (HAND) continues to be a debilitating disorder affecting the aging HIV patient population, even those who receive highly active antiretroviral therapy (ART). Despite this, the impact of DI on neurocognitive impairment remains largely unknown. This proposal intends on using the large, well-characterized CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort to identify DI in the blood and CNS and study its associations with the presence of HAND.
Recipients Awarded in 2013
Monica Guma, MD, PhD
Department of Medicine, Division of Rheumatology, Allergy and Immunology
Mentor: Gary Firestein, MD
Project Title: Choline Kinase: A Novel Target for Rheumatoid Arthritis
Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease that mainly affects the synovial joints leading to chronic inflammation, joint destruction and loss of function. Pathogenesis of the disease involves a complex interaction between the innate and the adaptive arm of the immune system in concert with the resident synovial fibroblasts. These fibroblasts-like synoviocytes (FLS), which display an aggressive/transformed phenotype, contribute to synovial inflammation and cartilage damage by producing inflammatory mediators, recruiting and activating immune cells, and invading articular cartilage. Although treatment of RA has improved, a significant proportion of patients are partial responders with continued disease activity. Furthermore, the currently available disease modifying drugs do not directly target FLS. Thus, new rationally designed disease modifying agents are needed to replace or complement current therapies.
Choline kinase (ChoKα) is an essential enzyme for phosphatidylcholine biosynthesis and is required for cell proliferation. The enzyme has also been implicated in cancer disease progression, metastasis, and invasiveness. Because choline-containing compounds are detected by magnetic resonance spectroscopy (MRS), increased levels of these compounds provide a non-invasive biomarker of transformation, staging and response to therapy in cancer. The unique tumor-like behavior of rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) led us evaluate whether this pathway could play a role in inflammation and joint damage due to synovitis. Therefore, we examined the expression and function of ChoKα in RA FLS and performed a targeted metabolomics assessment of this pathway. These studies suggest that ChoKα contributes to the rheumatoid aggressive phenotype and that ChoKα inhibition could be an effective strategy for arthritis.
Tatiana Kisseleva, MD, PhD
Division of Gastroenterology
Mentor: Michael Karin, PhD
Project Title: The Role of Epigenetics in Regulation of Hepatic Stellate Cell Activation
Abstract: Chronic liver injury results in hepatic fibrosis, in which quiescent Hepatic Stellate Cells (qHSCs) activate into myofibroblasts, depositing extensive extracellular matrix proteins (ECM). Cessation of fibrogenic stimuli often results in regression of liver fibrosis and is associated with the disappearance of activated HSCs (aHSCs)/myofibroblasts. We have recently demonstrated that some aHSCs apoptose, while other aHSCs inactivate (iHSCs) and obtain a quiescent-like phenotype. The overall goals of this Project are to identify the molecular factors that may prevent HSC activation into myofibroblasts, or that revert aHSC into a quiescent-like state. Our central hypothesis is that genome wide epigenetic changes regulate HSC phenotype by activation (or suppression) of transcriptional activity in HSCs. We also hypothesize that activation of PPARg-target genes regulates quiescent and inactivated HSC phenotypes. AIM1: To assess the genome wide methylation and acetylation sites using ChIP-Seq in qHSCs, aHSCs and iHSCs in order to identify motifs and transcription factors critical for HSC inactivation. Using the in vitro systems, we will determine if siRNA knock-down or overexpression of these factors blocks HSC activation, or triggers HSC inactivation. AIM2: We have demonstrated that PPARg is re-expressed in HSCs during inactivation. To gain a greater insight into the mechanisms of HSC inactivation, we will conduct a broad investigation of the epigenetic changes that regulate PPARg-target genes in distinct HSC phenotypes (qHSCs, aHSCs and iHSCs). We will test if functional inhibition of these genes compromise qHSC and iHSC phenotypes. AIM3: To assess the role of PPARg and PPARg target genes in HSC biology in vivo using conditional knockout mice, in which PPARg is constitutively or inducibly deleted specifically in HSCs. A specific role of PPARg in the maintenance of quiescent HSC phenotype and inactivation of aHSCs will be assessed in PPARg-deficient HSCs versus wild type HSCs. We anticipate that the collective results obtained in AIMs 1-3 will identify specific factors that can revert aHSCs into an inactivated quiescent-like state. AIM4: Our findings in mice must be applied to patients with fibrotic liver disease. To examine if HSC inactivation occurs in patients we will use flow cytometry: iHSCs will be identified as VitaminA+aSMA-GFAPlowPPARghi cells. Next, human HSCs will be subjected to ChIP-Seq analysis, and inactivation-specific targets will be identified (and compared to that in mice). The ability of these targets to inactivate human aHSCs into a quiescent-like state will be tested in vitro and in vivo using siRNA knock-down or intrahepatic transplantation of human HSCs into Rag2-/-gc-/- mice. The results of our studies will give new insight into mechanisms underlying HSC inactivation in mice and patients, identifying potential therapeutic targets that can induce inactivation of already existing HSCs/myofibroblasts in fibrotic liver.
James Murphy, MD, MS
Moores Cancer Center, Division of Clinical and Translational Research
Mentor: Loren Mell, MD
Project Title: Impact of Provider and Hospital Experience in Head-and-Neck Cancer
Abstract: Radiation therapy plays a primary role in the treatment of head-and-neck cancer, however the complex anatomy and high radiation doses required for cure leave little room for error.Suboptimal radiation therapy in the head-and-neck can lead to decreased survival or substantial long-term toxicity.The purpose of this study is to define the impact of radiation provider experience and treatment center experience on outcome in head-and-neck cancer.We will address these questions with a retrospective population-based longitudinal cohort study using SEER registry data linked to Medicare claims data.Competing risk models will determine whether physician or treatment center experience impacts overall survival, time to progression, or cancer-specific survival. Mixed effect multinomial logistic regression models will determine the impact of experience on long-term radiation toxicity.The findings from this study will be extremely useful for patients, physicians and policymakers alike.
Recipients Awarded in 2012
Kathryn Akong, MD
Department of Pediatrics
Mentor: Victor Nizet, MD
Project Title: Targeting HIF in Cystic Fibrosis Lung Disease
Abstract: Cystic fibrosis (CF) is a common inherited disease primarily affecting the lung and GI tract, caused by mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which encodes a chloride/bicarbonate channel. Chronic bronchopneumonia is a universal complication of this disorder, and is by far the most common cause of severe morbidity and premature mortality. The mechanistic link between impaired ion transport in epithelial cells and impaired host defense leading to chronic bronchopneumonia is not yet completely understood. There is no cure for CF, and current standard of care is targeted to improvement of airway mucus clearance and treatment of chronic bronchopneumonia with multiple prolonged courses of antibiotics. This approach inevitably leads to infection/colonization with highly antibiotic-resistant organisms, making treatment ever more challenging over time. The result of chronic bronchopneumonia and inflammation in CF is destruction of airways and lung parenchyma, leading to irreversible chronic obstructive lung disease.The purpose of my research is to discover new avenues to boost the immune system in clearing respiratory pathogens, as well as to minimize lung pathology associated with chronic inflammatory responses.
HIF-1α is an important master regulator of the innate immune system, and as such, is an attractive target for immune regulation in CF. Airway inflammation in CF is a double- edged sword, as too little may lead to increased bacterial infection, and too much may lead to increased airway injury and destruction. Modulation of HIF-1α activity can be a powerful therapeutic tool, as boosting its activity has been shown to improve host clearance of pathogens, and dampening its activity has been shown to minimize destructive effects of chronic inflammation.
Tiziano Pramparo, PhD
Department of Neurosciences
Mentor: Eric Courchesne, PhD
Project Title: Pathway-Based Sequencing and iPSCs Modeling of Autistic Patients
Abstract: Autism is a complex neurodevelopmental disorder with heritability that exceeds breast cancer, colon cancer, Alzheimer's disease, or schizophrenia. Currently, 80-90% of its etiology remains obscure and there are no strategies or biomarkers for early detection, and treatments are still ineffective. Brain enlargement with overabundance of neurons is detected at young ages, suggesting that mechanisms regulating cell number may be disrupted prenatally. We detected altered expression levels of developmental pathways, cell cycle and apoptosis genes in peripheral blood of young living patients and validated these findings using young postmortem brain tissue.
The substantial overlap of dysregulated pathways between the two tissues lays a solid base to develop an innovative, hypothesis- driven approach to dissect a possible molecular mechanism of gene dysregulation, such as rare genomic variants in regulatory sequences of the genes involved. Moreover, due to the complexity of the disorder, we aim to model these alterations in vitro using the innovative iPSC technology that will allow a deeper study of the disrupted biology as well the future testing of molecules to recover or ameliorate the cellular phenotypes. In turn, this will translate into the development of potential treatments and a step forward to Autism personalized medicine.
Recipients Awarded in 2011
Michael Donohue, PhD
Division of Biostatistics and Bioinformatics
Mentor: Paul Aisen, MD
Project Title: Efficient Models for Longitudinal Data with Missingness, with Application to Alzheimer's Disease Clinical Trials
Abstract: Randomized clinical trials of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) typically assess intervention efficacy with measures of cognitive or functional assessments repeated every six months for one to two years. Models that treat time as categorical are gaining popularity because they make no assumptions about the shape of the mean trajectory of the outcome over time. However, in some cases categorical time models may be over parameterized and inefficient in detecting treatment effects relative to continuous time models of, say, the linear trend of the outcome over time. Linear mixed effects models can also be extended to model quadratic or cubic time effects, or incorporate smoothing splines, although it is questionable whether the duration and interval of observations in AD and MCI studies is sufficient to support such models. Furthermore, it is unknown which of these models are most robust to missing data, which plagues AD and MCI studies. We will conduct meta analyses characterizing patterns of observed missingness and applying the competing models to data from 23 drug studies conducted by the Alzheimer's Disease Cooperative Study (ADCS). Efficiency will be compared using analytic methods and simulation studies; and new models will be proposed for robust primary inference and missing data sensitivity analyses.
Maile Ann Young Karris, MD
Division of Infectious Diseases
Mentor: Douglas Richman, MD
Project Title: Validation of an In Vitro Primary CD4+ T Cell Model of HIV
Abstract: The ability of HIV to integrate into long-lived resting CD4+ T cells prevents the eradication of HIV even with extended courses of antiretroviral therapy. It is believed that a cure could be achieved with the development of approaches targeting this latently infected reservoir. Our understanding of the mechanisms surrounding the establishment and maintenance of HIV latency however remain incomplete. The infrequency of latently infected cells in vivo and the lack of biologically relevant in vitro models complicate the study of latency. To address these issues, we utilized an in vitro primary CD4+ T cell model in which non-dividing, resting lymphocytes were infected in the presence of activated, productively infected cells.
Latent infection of replication competent HIV was established in both memory and naive CD4+ cells, which mirrors in vivo observations of SIV infected macaques, and HIV infected humans in which non-activated, non-dividing naïve and memory CD4+ T cells are frequently infected. We posit that our in vitro model reflects cell-virus interactions in vivo. To support this hypothesis and validate the in vitro model we propose to characterize the latently infected resting CD4+ T cell subsets (naïve, central memory, effector memory) of HIV positive patients taking suppressive antiretroviral therapy.
Loren K. Mell, MD
Department of Radiology
Mentor: Arno Mundt, MD
Project Title: Prospective Multi-Center Clinical Trial of Pelvic Organ-Sparing Intensity Modulated Radiation Therapy and Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma
Abstract: Cervical cancer is a leading cause of cancer mortality in women, with increasing incidence in developing countries. Many women present with advanced disease for which cisplatin and pelvic radiation therapy (RT) is standard treatment. This treatment is limited, however, by high rates of failure and toxicity. Strategies to reduce toxicity and increase efficacy of chemoradiotherapy are needed. Combining cisplatin/RT with additional chemotherapy can improve tumor control, but results in unacceptably high toxicity. Reducing radiation to normal tissues like bowel and bone marrow may reduce toxicity, permitting the delivery of more intensive chemotherapy. We have developed techniques to reduce radiation dose to pelvic organs while maintaining high doses to the target, using a novel approach called intensity modulated radiation therapy (IMRT). IMRT differs from conventional RT by using multiple beam angles and computerized planning algorithms to conform radiation dose to the target. Multiple preliminary studies indicate that IMRT can significantly reduce toxicity of chemoradiotherapy and improve chemotherapy delivery, but this hypothesis has not been tested in clinical trials. Our long-term goal is to compare IMRT versus conventional RT in a multi-center randomized trial. Our first step is to assess toxicity, feasibility, and quality of IMRT in an international phase II trial.
Recipients Awarded in 2010
Taylor Alan Doherty, MD
Department of Medicine
Mentor: David Broide, MB, ChB
Project Title: Targeting OX40/OX40L as a Novel Therapy for Chronic Asthma and Remodeling
Abstract: Approximately 7% of the US population has asthma, representing a significant public health and economic burden. Allergic asthma is thought to be orchestrated by cells of the immune system termed "T cells" that respond inappropriately to inhaled allergens. The normal non-allergic immune system develops tolerance to these environmental allergens, but allergic individuals have T cells that remain reactive. One molecule that appears to be critical to the development of these reactive T cells is OX40. I will be studying the role of OX40 using an animal model of chronic asthma as well as in samples from patients with allergic asthma. Our hypothesis is that blocking OX40 will reduce allergic responses and perhaps lead to future treatments for this disease.
Sonia L. Ramamoorthy, MD, FACS, FASCRS
Department of Surgery
Mentor: John Carethers, MD
Project Title: Neoplastic Transformation in Squamous Cell Cancer of the Anus
Abstract: Squamous cell cancer of the anus (anal cancer) is increasing in frequency in the general population in the United States, Europe and South America. Infection with "high risk" serotypes of human papillomavirus (HPV), HPV 16 and HPV 18, play a causative role in the development of anal dysplasia, a precursor lesion to anal cancer. What is poorly understood is the transformation from conditions of dysplasia to invasive cancer. We propose to examine a cohort of patients with anal dysplasia and anal cancer from our institution in whom we have obtained clinical data, including oncologic outcomes and risk factors such as tobacco usage, HIV disease, and molecular and inflammatory data directly from formalin fixed tissue. Our first aim is to study the inflammatory events involved with anal cancer and how this impacts clinical outcome. Our second aim is to investigate the role of a synchronous viral pathogen, JC virus, that is found within the GI tract and its role as a co-factor with HPV in neoplastic transformation from anal dysplasia to invasive anal cancer. Elucidating the process by which these cells undergo transformation will aid in our understanding of viral oncogenesis, and cell immunity in anal cancer development as it relates to cancer outcomes.